By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

The Medicines Company 

8 Sylvan Way

Parsippany  New Jersey  07054  U.S.A.
Phone: 973-290-6000 Fax: 973-656-9898


SEARCH JOBS



The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.



Key Statistics


Email: contactus@themedco.com
Ownership: Public

Web Site: The Medicines Company
Employees: 500+
Symbol: MDCO
 





Collaborations

UCB, Inc.  Contract manufacturing of Bivalirudin peptide active ingredient

Alnylam 





Company News
The Medicines Company (MDCO) To Announce Second Quarter Financial Results On July 27, 2016 7/18/2016 9:55:09 AM
Federal Circuit Rules For The Medicines Company (MDCO) In Angiomax (Bivalirudin) Patent Litigation 7/12/2016 10:47:00 AM
The Medicines Company (MDCO) Announces Positive Top- Line Results For Phase 3 TANGO 1 Clinical Trial Of CARBAVANCE 6/27/2016 9:42:47 AM
The Medicines Company (MDCO) Completes Divestiture Of Its Non-Core Cardiovascular Assets To Chiesi 6/22/2016 11:24:22 AM
The Medicines Company (MDCO) Announces Initiation Of Phase II Study For Its Investigational Anesthetic, ABP-700 6/14/2016 7:50:18 AM
The Medicines Company (MDCO) Announces Participation At ASM MICROBE 2016 To Be Held June 16 – 20 In Boston 6/13/2016 10:25:10 AM
The Medicines Company (MDCO) Prices $350 Million Of Convertible Notes 6/7/2016 11:04:58 AM
The Medicines Company (MDCO) Announces Intention To Offer $350 Million Of Convertible Notes 6/6/2016 11:56:14 AM
The Medicines Company (MDCO) Completes Patient Enrollment For ORION-1 Study Of PCSK9si 6/2/2016 11:44:55 AM
The Medicines Company (MDCO) Announces Completion Of Patient Enrollment In Phase 3 TANGO 1 Study Of CARBAVANCE (Meropenem-Vaborbactam) For Treatment Of Complicated Urinary Tract Infections (cUTI) 5/27/2016 11:10:14 AM
12345678910...
//-->